Aevius
Category: AI in Healthcare
Mass General Brigham spinout building multimodal foundation models of longitudinal patient histories to make medicine computable for health systems, payers and life sciences firms. Aevius was founded in 2026. The company is led by Rowland Pettit. Based in Boston, United States. Total funding raised: $22M. Latest round: Seed. Key investors include Insight Partners.
- Founded
- 2026
- Headquarters
- Boston, United States
- Total funding
- $22M
Value proposition
Turns fragmented structured, unstructured and multimodal clinical data into a refreshable, computable multimodal patient representation. Teams and AI agents can build many clinical and operational applications on one reusable foundation instead of reconstructing patient context one text query at a time.
Products and solutions
Clinical intelligence platform of foundation models trained on structured EHR tables, clinical notes, and specialty data (pathology, imaging, genomics). Supports outcome forecasting, clinically similar patient search, population identification and stratification, longitudinal disease progression monitoring, candidate biomarker discovery, and clinical trial cohort identification.
Unique value
A native, longitudinal multimodal patient representation covering the whole patient, rather than text-only LLM agents that piece together context per query.
Target customer
Health systems, payers (health plans) and life sciences/biopharma companies
Industries served
Healthcare delivery, health plans/payers, biopharma and life sciences
Technology advantage
Founding team built and commercialized medical AI at Modella AI (acquired by AstraZeneca). Research lineage from Mass General Brigham, including Faisal Mahmood's lab. Eric Topol chairs the Scientific Advisory Board.
How they differentiate
Multimodal, longitudinal patient-level foundation models rather than text-only LLM agents or data-aggregation platforms. One reusable patient representation serves multiple downstream applications.
Main competitors
Tempus AI, Truveta, Komodo Health
Key partnerships
Spun out of Mass General Brigham, which provides the research lineage
Major milestones
Launched from stealth on Nov 17, 2026 with a $22M seed round led by Insight Partners. Spun out of Mass General Brigham. Founders previously built Modella AI, acquired by AstraZeneca in Jan 2026.
Market positioning
Enterprise clinical intelligence / medical foundation model company, launched from stealth at seed stage with MGB provenance and a founder team with a prior AstraZeneca exit.
Geographic focus
United States
About Rowland Pettit
Co-founder of Modella AI (acquired by AstraZeneca, Jan 2026); former venture investor and operator; MD/PhD from Harvard Medical School with clinical pathology residency.
Latest news about Aevius
More AI in Healthcare companies
Official website: https://aevius.ai